Portugal medical device registration timeline
Source-linked clocksNational Authority of Medicines and Health Products (INFARMED) review clocks and end-to-end planning ranges, using the 4-class (I, IIa, IIb, III) — EU MDR classification system.
| Class / pathway | Review clock | Planning total | With prior approval | Provenance |
|---|---|---|---|---|
| Class I(Self-declaration (no notified body)) MDR Art. 52(7): non-sterile, non-measuring, non-reusable-surgical Class I devices are self-declared, so no authority or notified body reviews the file and there is no review clock Elapsed time is Eudamed actor and device registration, which has no guaranteed processing time, plus any national registration duty | 0 days | 6-9 months | — | Verified |
Planning steps and estimates; these are not regulator deadlines.
Portugal Medical Device Registration Process
Step-by-step INFARMED registration process. Total estimated timeline: 6-9 months.
Step 1: Pre-Submission Preparation
1-3 monthsGather technical documentation, quality management system (QMS) records, and clinical data required by INFARMED. Appoint a EU Authorized Representative.
Step 2: Application Submission
1-2 weeksSubmit complete registration dossier to INFARMED including device description, risk analysis, and testing reports.
Step 3: Administrative Review
2-4 weeksINFARMED reviews application for completeness. May request additional documents or clarifications.
Step 4: Technical Evaluation
0 daysIn-depth technical assessment of device safety and performance. INFARMED may issue questions.
Step 5: Registration Approval
1-2 weeksUpon successful review, INFARMED issues Portugal market authorization certificate.
- EU Authorized Representative (for non-EU manufacturers)
- Field safety corrective action: preliminary INFARMED submission within 2 days before informing users (Decree-Law 145/2009 as amended by Lei 27/2022, applied to MDR/IVDR by Lei 71/2025)
- Lei 71/2025 applies MDR/IVDR assessment clocks directly to national procedures
Reviewed 2026-08-29. End-to-end totals remain planning estimates.